Structured Summary:
In patients with diabetic macular edema, intravitreal aflibercept combined with dexamethasone phosphate significantly improved short-term structural and functional outcomes compared to intravitreal aflibercept alone, though it was associated with increased intraocular pressure as a main side effect.
| PICO | Description |
|---|---|
| Population | Adults diagnosed with diabetic macular edema (DME). |
| Intervention | Combination therapy of intravitreal aflibercept and dexamethasone sodium phosphate. |
| Comparison | Intravitreal aflibercept monotherapy. |
| Outcome | The combination therapy resulted in improved short-term structural (retinal thickness) and functional (visual acuity) outcomes compared to aflibercept alone. However, it was associated with increased intraocular pressure. |
Source: Valesca Castro Neri, et al. “Intravitreal aflibercept alone versus combination with dexamethasone phosphate for diabetic macular edema: A randomized phase-2 clinical trial.” Read article here.
